BCR and pachyonychia congenita: Since ART can be offered to patients with PM, pT3 disease, and high-grade localized PC [14], we tested IDC-P’s stand-alone impact on BCR in patients without those HRF, who would have never been considered for ART (n = 148, 19 BCR, median follow-up time of 116 months [IQR: 83–139]).